Clearstead Trust LLC Lowers Stock Position in Medtronic PLC $MDT

Clearstead Trust LLC cut its position in shares of Medtronic PLC (NYSE:MDT) by 88.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,246 shares of the medical technology company’s stock after selling 9,593 shares during the quarter. Clearstead Trust LLC’s holdings in Medtronic were worth $119,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Marks Group Wealth Management Inc increased its stake in Medtronic by 2.3% in the 3rd quarter. Marks Group Wealth Management Inc now owns 29,497 shares of the medical technology company’s stock valued at $2,809,000 after buying an additional 671 shares during the last quarter. Washington Trust Advisors Inc. grew its holdings in shares of Medtronic by 15.9% in the third quarter. Washington Trust Advisors Inc. now owns 853 shares of the medical technology company’s stock valued at $81,000 after acquiring an additional 117 shares in the last quarter. Quantum Private Wealth LLC increased its position in shares of Medtronic by 18.0% during the third quarter. Quantum Private Wealth LLC now owns 3,021 shares of the medical technology company’s stock valued at $288,000 after acquiring an additional 461 shares during the last quarter. Vestmark Advisory Solutions Inc. increased its position in shares of Medtronic by 9.9% during the third quarter. Vestmark Advisory Solutions Inc. now owns 17,659 shares of the medical technology company’s stock valued at $1,682,000 after acquiring an additional 1,592 shares during the last quarter. Finally, Westerkirk Capital Inc. lifted its holdings in Medtronic by 49.7% during the third quarter. Westerkirk Capital Inc. now owns 10,578 shares of the medical technology company’s stock worth $1,007,000 after acquiring an additional 3,510 shares during the period. 82.06% of the stock is owned by institutional investors.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Received CE mark for its next‑gen GI Genius module and ColonPRO software — expands regulatory clearance and commercial runway in GI imaging, a clear revenue catalyst. Medtronic wins CE mark for next-gen GI Genius module, ColonPRO software
• Positive Sentiment: Recognized at the 2026 Dorian Awards for structured problem‑solving excellence — a reputational boost that supports brand value with hospitals and enterprise customers. 2026 DORIAN AWARDS RECOGNIZE GLOBAL LEADERS IN STRUCTURED PROBLEM-SOLVING EXCELLENCE
• Positive Sentiment: Multiple investor pieces highlight Medtronic’s strong dividend profile and defensive cash flows, reinforcing interest from income-seeking investors and supporting the share price floor. 1 Reason I’d Buy Medtronic Stock and Never Sell
• Neutral Sentiment: BTIG maintained a Hold rating on MDT — not bearish but keeps analyst sentiment from turning strongly positive. BTIG Sticks to Its Hold Rating for Medtronic (MDT)
• Neutral Sentiment: Valuation/returns analysis pieces point to mixed long‑term returns and prompt investors to reassess fair value — supports trading volatility but not a clear directional signal. Is It Time To Reconsider Medtronic (MDT) After Mixed Long Term Share Returns
• Neutral Sentiment: Industry podcast and revenue roundups highlight broader medtech winners from 2025 — useful context for sector positioning but not company‑specific catalysts. Podcast: Which pharma and medtech companies came out on top in 2025 revenues?
• Neutral Sentiment: Coverage of broader trade/tariff uncertainty underscores a macro risk — CEOs want policy clarity, which could affect multinational supply chains and sentiment for global medtech firms like Medtronic. Veteran CEO: President Trump’s chaotic tariff policy is not working

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on MDT. Barclays reaffirmed an “overweight” rating and set a $118.00 target price on shares of Medtronic in a research report on Wednesday, February 18th. Sanford C. Bernstein raised their price objective on shares of Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a report on Friday, January 9th. Leerink Partners dropped their target price on shares of Medtronic from $120.00 to $119.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 18th. Weiss Ratings restated a “buy (b-)” rating on shares of Medtronic in a research note on Monday, December 29th. Finally, Wall Street Zen raised shares of Medtronic from a “hold” rating to a “buy” rating in a report on Saturday. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $110.84.

Medtronic Price Performance

MDT opened at $98.54 on Tuesday. The firm has a 50-day moving average price of $99.03 and a 200-day moving average price of $96.80. Medtronic PLC has a twelve month low of $79.55 and a twelve month high of $106.33. The company has a quick ratio of 1.80, a current ratio of 2.42 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $126.33 billion, a price-to-earnings ratio of 27.45, a PEG ratio of 2.43 and a beta of 0.71.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.88%. The company had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. During the same period last year, the firm earned $1.38 EPS. Medtronic’s revenue for the quarter was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts expect that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were paid a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date was Friday, December 26th. Medtronic’s payout ratio is presently 79.11%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).